Reaction

Concomitant Disease Progression reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,949 reports · 45 co-occurring drugs

As of the last recalculation, Concomitant Disease Progression appears in 1,949 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is EVEROLIMUS TABLETS (PRR 20.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Everolimus Tablets	31	20.0	20.1
Everolimus	86	18.8	18.9
Nilotinib	50	18.6	18.6
Deferasirox	45	18.5	18.6
Tolvaptan	24	17.8	17.9
Bosentan	78	17.2	17.2
Canakinumab	15	14.9	14.9
Imatinib	23	14.1	14.1
Epoprostenol	17	14.0	14.0
Amlodipine Besylate And Benazepril Hydrochloride	12	14.0	14.0
Octreotide Acetate	36	12.8	12.8
Enalapril	61	12.1	12.1
Imatinib Mesylate	31	12.0	12.1
Enalapril Maleate	27	11.8	11.8
Selexipag	28	11.7	11.7
Cyclosporine	115	11.7	11.7
Sildenafil Powder,	36	11.0	11.0
Macitentan	68	10.8	10.8
Zoledronic Acid	37	10.0	10.0
Rivastigmine	17	9.7	9.7
Moxifloxacin	12	9.1	9.2
Mycophenolic Acid	27	9.1	9.1
Metolazone	9	8.6	8.6
Moxifloxacin Hydrochloride	16	8.5	8.5
Theophylline	9	8.4	8.4
Basiliximab	9	8.2	8.2
Ranibizumab	20	8.1	8.1
Sildenafil	43	8.1	8.1
Dabrafenib	14	7.1	7.1
Letrozole	39	6.9	6.9
Paricalcitol	9	6.8	6.8
Ribociclib	20	6.8	6.8
Oseltamivir	5	6.7	6.7
Eplerenone	8	6.7	6.7
Doxazosin	17	6.5	6.5
Febuxostat Tablets 40 Mg	6	6.3	6.3
Febuxostat Tablets 80 Mg	6	6.3	6.3
Trametinib	14	6.2	6.2
Sildenafil Citrate	70	6.1	6.1
Amlodipine Besylate And Valsartan	6	5.8	5.8
Micafungin Sodium	4	5.0	5.0
Sacubitril And Valsartan	49	4.6	4.6
Pazopanib Hydrochloride	11	4.4	4.4
Riociguat	13	4.3	4.3
Pirfenidone	8	2.1	2.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.